CATCH-UP GROWTH DURING TOCILIZUMAB THERAPY FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 2-YEAR DATA FROM A PHASE 3 CLINICAL TRIAL

被引：0
|
作者：
De Benedetti, F. [1 ]
Ruperto, N. [2 ]
Espada, G. [2 ]
Gerloni, V. [2 ]
Flato, B. [3 ]
Horneff, G. [2 ]
Myones, B. [4 ]
Onel, K. [4 ]
Frane, J.
Wang, J. [5 ]
Lipman, T. [6 ]
Bharucha, K. [7 ]
Martini, A. [2 ]
Lovell, D. [4 ]
机构：
[1] IRCCS Osped Pediat Bambino Gesu, Rome, Italy
[2] PRINTO, Genoa, Italy
[3] OUS, Oslo, Norway
[4] PRCSG, Cincinnati, OH USA
[5] Roche, Welwyn Garden City, England
[6] U Penn Sch Nursing, Philadelphia, PA USA
[7] Genentech Inc, San Francisco, CA 94080 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：729 / 730
页数：2
相关论文
共 50 条
  • [41] Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program
    Grom, Alexei A.
    Brunner, Hermine I.
    Ruperto, Nicolino
    Martini, Alberto
    Lovell, Daniel
    Pascual, Virginia
    Lheritier, Karine
    Leon, Karolynn
    Abrams, Ken
    Ilowite, Norman
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [42] LONG-TERM PROGNOSTIC FOLLOW-UP OF PATIENTS WITH REFRACTORY SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS AFTER THE CLINICAL TRIAL OF TOCILIZUMAB AS A FIRST-LINE BIOLOGIC TREATMENT
    Miyamae, T.
    Kawabe, T.
    Nishimura, K.
    Hattori, S.
    Imagawa, T.
    Ishii, T.
    Ito, S.
    Iwata, N.
    Kamata, Y.
    Kamiyama, Y.
    Mizuta, M.
    Mori, M.
    Murase, A.
    Nakagishi, Y.
    Nakano, T.
    Nakayamada, S.
    Nozawa, T.
    Ohya, T.
    Okamoto, N.
    Sato, K.
    Sugita, Y.
    Takei, S.
    Tanaka, Y.
    Tomiita, M.
    Umebayashi, H.
    Yamasaki, Y.
    Nishimoto, N.
    Yokota, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 671 - 672
  • [43] Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial
    Emery, Paul
    McInnes, Iain B.
    Mease, Philip J.
    Schiff, Michael
    Pricop, Luminita
    Shen, Steven
    Wang, Zailong
    Gaillez, Corine
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [44] SECUKINUMAB SUSTAINS INDIVIDUAL CLINICAL RESPONSES OVER TIME IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL, FUTURE 2
    Emery, P.
    McInnes, I. B.
    Mease, P. J.
    Schiff, M.
    Pricop, L.
    Shen, S.
    Wang, Z.
    Gaillez, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1329 - 1329
  • [45] Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
    Brunner, Hermine I.
    Ruperto, Nicolino
    Zuber, Zbigniew
    Keane, Caroline
    Harari, Olivier
    Kenwright, Andrew
    Lu, Peng
    Cuttica, Ruben
    Keltsev, Vladimir
    Xavier, Ricardo M.
    Calvo, Inmaculada
    Nikishina, Irina
    Rubio-Perez, Nadina
    Alexeeva, Ekaterina
    Chasnyk, Vyacheslav
    Horneff, Gerd
    Opoka-Winiarska, Violetta
    Quartier, Pierre
    Silva, Clovis A.
    Silverman, Earl
    Spindler, Alberto
    Baildam, Eileen
    Luz Gamir, M.
    Martin, Alan
    Rietschel, Christoph
    Siri, Daniel
    Smolewska, Elzbieta
    Lovell, Daniel
    Martini, Alberto
    De Benedetti, Fabrizio
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) : 1110 - 1117
  • [46] Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis - an Extension Study of 2 Phase 1b Clinical Trials
    Brunner, Hermine
    Ramanan, Athimalaipet
    Horneff, Gerd
    Minden, Kirsten
    Calvo Penades, Inmaculada
    Zucchetto, Mauro
    Brockwell, Laura
    Gordon, Oliver
    De Benedetti, Fabrizio
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4390 - 4393
  • [47] 2-year data: Infliximab maintains clinical response in psoriatic arthritis patients-data from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni, CE
    Kavanaugh, A
    Kirkham, B
    Tutuncu, ZN
    Burmester, G
    Schneider, U
    Furst, DE
    Moliter, J
    Keystone, EC
    Gladman, D
    Manger, B
    Wassenberg, S
    Weier, R
    Wallace, D
    Weisman, M
    Kalden, JR
    Smolen, JS
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S209 - S209
  • [48] Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial.
    Khanna, Dinesh
    Denton, Christopher P.
    van Laar, Jacob M.
    Jahreis, Angelika
    Cheng, Sabrina
    Spotswood, Helen
    Siegel, Jeffrey
    Furst, Daniel E.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S386 - S386
  • [49] Rapid improvement of signs and symptoms associated with systemic juvenile idiopathic arthritis (sJIA) by interleukin-6 (IL-6) blockade-results from a tocilizumab sJIA phase III clinical trial.
    Yokota, Shumpei
    Imagawa, Tomoyuki
    Mori, Masaaki
    Takei, Syuji
    Yoshifumi, I
    Iwata, Naomi
    Tomiita, Minako
    Miyoshi, Mari
    Aihara, Yuko
    Murata, Takuji
    Abukawa, Daiki
    Nishimoto, Norihiro
    Kishimoto, Tadamitsu
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S327 - S327
  • [50] BIMEKIZUMAB REDUCED PSORIATIC ARTHRITIS IMPACT IN PATIENTS WITH PSORIASIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
    Gossec, Laure
    Gladman, Dafna D.
    Gisondi, Paolo
    de Wit, Maarten
    Ogdie, Alexis
    Ink, Barbara
    Taieb, Vanessa
    Lambert, Jeremy
    Coates, Laura C.
    [J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
12345